Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
European journal of dermatology : EJD - 33(2023), 6 vom: 01. Dez., Seite 680-685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cohen, Elisabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/ejd.2023.4584 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369552865 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369552865 | ||
| 003 | DE-627 | ||
| 005 | 20240312234459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1684/ejd.2023.4584 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM369552865 | ||
| 035 | |a (NLM)38465550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cohen, Elisabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cutaneous sarcoidosis | |
| 650 | 4 | |a first-line treatment | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a sarcoidosis | |
| 650 | 4 | |a systemic corticosteroids | |
| 650 | 4 | |a topical steroids | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Lheure, Coralie |e verfasserin |4 aut | |
| 700 | 1 | |a Ingen-Housz-Oro, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Hotz, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Bettuzzi, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Chasset, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Descamps, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Deschamps, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Mahevas, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Sohier, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Guegan, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Kramkimel, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Darbord, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Chanal, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Oulès, Benedicte |e verfasserin |4 aut | |
| 700 | 1 | |a Aractingi, Selim |e verfasserin |4 aut | |
| 700 | 1 | |a Seta, Vannina |e verfasserin |4 aut | |
| 700 | 1 | |a Dupin, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of dermatology : EJD |d 1996 |g 33(2023), 6 vom: 01. Dez., Seite 680-685 |w (DE-627)NLM091612039 |x 1952-4013 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:6 |g day:01 |g month:12 |g pages:680-685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/ejd.2023.4584 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 6 |b 01 |c 12 |h 680-685 | ||